Targeted therapy with MXD3 siRNA, anti-CD22 antibody and nanoparticles for precursor B-cell acute lymphoblastic leukaemia.

Targeted therapy with MXD3 siRNA, anti-CD22 antibody and nanoparticles for precursor B-cell acute lymphoblastic leukaemia. Br J Haematol. 2014 Nov; 167(4):487-99.

View in: PubMed

subject areas

Animals
Antibodies, Monoclonal, Murine-Derived
Antibodies, Neoplasm
Female
Humans
Magnetite Nanoparticles
Male
Mice
Mice, Inbred NOD
Mice, Knockout
Mice, SCID
Neoplasm Proteins
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Repressor Proteins
RNA, Small Interfering
Sialic Acid Binding Ig-like Lectin 2
Xenograft Model Antitumor Assays

authors with profiles

Nitin Nitin